Latest Administration News

Page 96 of 184
Civmec Limited reported a 21.6% drop in revenue and a 34% fall in net profit for FY2025, reflecting the impact of completed contracts. Despite this, the company maintained steady margins and increased its cash reserves, signaling resilience and ongoing growth potential.
Victor Sage
Victor Sage
28 Aug 2025
Steadfast Group reported a robust FY25 with underlying NPAT rising 17.2% to $295.5 million, driven by strong organic growth and strategic acquisitions in the US and UK. The insurer broker continues to invest in technology and international expansion while raising dividends.
Claire Turing
Claire Turing
28 Aug 2025
Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.
Ada Torres
Ada Torres
28 Aug 2025
Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.
Victor Sage
Victor Sage
28 Aug 2025
Dominion Income Trust 1 (DN1) has reported a solid start with a $7.3 million profit and $345.9 million in net assets for its inaugural half-year period ending June 2025. The Trust raised $345.45 million through unit offers and delivered a 2.61% net return.
Claire Turing
Claire Turing
28 Aug 2025
CPT Global Limited reported a 12% revenue increase to $23.1 million for FY2025, driven by growth in the Northern Hemisphere segment, while narrowing its net loss to $706,214. The company is strategically pivoting towards larger markets and investing in technology and talent to fuel future growth.
Victor Sage
Victor Sage
28 Aug 2025
Income Asset Management Group reported a robust FY2025 with significant revenue and client growth, alongside strategic cost reductions and a new product launch planned for FY26.
Claire Turing
Claire Turing
28 Aug 2025
Income Asset Management Group reported a 22% revenue increase and a significant reduction in net loss for FY25, underpinned by strategic cost cuts, debt repayment, and governance enhancements. The Group also launched a new managed account product and announced key board changes.
Claire Turing
Claire Turing
28 Aug 2025
Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.
Ada Torres
Ada Torres
28 Aug 2025
Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.
Ada Torres
Ada Torres
28 Aug 2025
Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.
Ada Torres
Ada Torres
28 Aug 2025
Salter Brothers Emerging Companies Limited posted a 25.5% decline in profit after tax for FY25 but marked a milestone with its inaugural dividend payment. The fund remains confident in its small-cap investment strategy amid easing interest rates and geopolitical volatility.
Claire Turing
Claire Turing
28 Aug 2025